Affiliation:
1. Beihai Hospital of Chinese Medicine Beihai Guangxi China
2. State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Science Guangxi Normal University Guilin China
Abstract
RationaleIsopsoralen (ISO), a quality control marker (Q‐marker) in Psoraleae Fructus, is proven to present an obvious anti‐osteoporosis effect. Until now, the metabolism and anti‐osteoporosis mechanisms of ISO have not been fully elucidated, greatly restricting its drug development.MethodsThe metabolites of ISO in rats were profiled by using ultrahigh‐performance liquid chromatography coupled with time‐of‐flight mass spectrometry. The potential anti‐osteoporosis mechanism of ISO in vivo was predicted by using network pharmacology.ResultsA total of 15 metabolites were characterized in rats after ingestion of ISO (20 mg/kg/day, by gavage), including 2 in plasma, 12 in urine, 6 in feces, 1 in heart, 3 in liver, 1 in spleen, 1 in lung, 3 in kidney, and 2 in brain. The pharmacology network results showed that ISO and its metabolites could regulate AKT1, SRC, NFKB1, EGFR, MAPK3, etc., involved in the prolactin signaling pathway, ErbB signaling pathway, thyroid hormone pathway, and PI3K‐Akt signaling pathway.ConclusionsThis is the first time for revealing the in vivo metabolism features and potential anti‐osteoporosis mechanism of ISO by metabolite profiling and network pharmacology, providing data for further verification of pharmacological mechanism.
Funder
National Natural Science Foundation of China